The FDA granted a fast track designation to IMM-1-104 (Immuneering Corp.) to treat patients with unresectable or metastatic NRAS-mutant melanoma whose disease progressed or is intolerant to PD-1-/PD-L1-based immune checkpoint inhibitors.1 Currently, the treatment is undergoing evaluation in a phase 2a clinical trial (NCT05585320)2, which enrolled patients with advanced solid tumors, including melanoma.
2024
Does Indoor Tanning Affect Melanoma Tumor Mutational Burden?
Indoor tanning exposure was not associated with tumor mutational burden (TMB) in patients with cutaneous melanoma, in a retrospective cohort study. Higher TMB was linked to older age, head and neck tumors, and a history of nonmelanoma skin cancer (NMSC).
Medical mismanagement may contribute to worse survival outcomes for invasive melanoma
Patients with upstaged tumors saw an overall mortality rate of 36% vs. 19.5% in their non-upstaged counterparts.
Melanoma survival linked to tumor thickness
Researchers at The University of Sydney have identified a significant increase in melanoma-related death risk for patients with thin primary tumors measuring between 0.8 and 1.0 millimeters compared to those with thinner lesions.